The case for & against
Bull & Bear analysis
RxSight, Inc. (NASDAQ:RXST) specializes in advancing ocular surgical technologies, particularly through its proprietary Light Adjustable Lens (LAL) platform aimed at enhancing visual outcomes for cataract surgery patients. Positioned in the premium intraocular lens (IOL) market, RxSight is navigating a competitive landscape, emphasizing its unique technology to offer customizable vision options. The company has recently focused on expanding its reach into international markets, with strategic plans for growth and recovery after facing operational challenges and declining sales.
Bull says
- ↑Proprietary LAL platform uniquely differentiates RxSight in premium IOL market
- ↑Q1 gross margin rose to 76.1% from 74.8% YoY, reflecting improved product mix
- ↑New Zealand approval achieved, with international sales set to scale significantly by 2027
- ↑Customer re-engagement programs show early success boosting practice adoption
- ↑High book-to-price ratio indicates undervaluation and strong institutional ownership
- ↑Robust balance-sheet liquidity supports R&D and potential shareholder returns
Bear says
- ↓Q1 2026 sales declined 18% YoY to $30.9M, signaling demand weakness
- ↓Net loss widened to $15.9M as SG&A rose 11% YoY, compressing margins
- ↓Full-year revenue guidance held at $120–135M amid cautious recovery outlook
- ↓Premium IOL reimbursement cuts and macro pressures risk customer adoption
- ↓Negative profitability metrics and elevated leverage heighten financial risk
- ↓Weak stock momentum and small scale suggest limited downside buffers
Investment themes with RXST
Clinical instruments and devices powering patient care
Stocks with highest short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- LAL is unique in that it's broadly applicable to patients because it does preserve quality of vision. It's very flexible and it appeals intuitively to this next generation of patients who not only want to maintain their function throughout many conditions, but they also want to have control and an input in the process.
- we are very focused on providing what I'd say are the highest levels of clinical training and field support, both here in the U.S. and also abroad, which requires investment.
- marked an important milestone, 300,000 LAL implants since commercialization in the US. In addition, we launched our I Trust It With My Own Eyes campaign, featuring ophthalmologists who have chosen the light-adjustable lens for their own eyes, reinforcing the level of confidence doctors have in the LAL's ability to deliver high-quality, customized binocular vision.
Bear points
- Q1 sales of $30.9 million declined 18%, reflecting a year-over-year step down in LDD unit volumes consistent with expectations.
- First quarter, 2026 SG&A expenses were $31.9 million, up 11% compared to the prior year period, driven by personnel-related expenses as we continue to prioritize investments in new hires and ongoing expansion of our global commercial and support teams.
- We reported a net loss in the first quarter of $15.9 million, or $0.38 per basic and diluted share, based on 41.3 million weighted average shares outstanding.